Reproductive factors in relation to breast cancer characterized by p53 protein expression (United States)

Cancer Causes and Control

Volumn 14, Issue 7, 2003, Pages 609-618

  Furberg, Helena ^a   Millikan, R C ^b   Geradts, J ^c   Gammon, M D ^b   Dressler, L G ^b   Ambrosone, C B ^a   Newman, B ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Breast cancer; p53 expression; Risk factors

Indexed keywords

ORAL CONTRACEPTIVE AGENT; PROTEIN P53;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CONFIDENCE INTERVAL; CONTRACEPTION; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCTION; UNITED STATES;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CONTRACEPTIVES, ORAL; ENVIRONMENTAL EXPOSURE; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NORTH CAROLINA; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0141528675     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025682410937     Document Type: Article

References (46)

1. Kelsey JL, Gammon MD, John EM (1993) Reproductive factors and breast cancer. Epidemiol Rev 15: 36-47.
2. Hall IJ, Newman B, Millikan RC, Moorman PG (2000) Body size and breast cancer risk in black women and white women: the Carolina Breast Cancer Study. Am J Epidemiol 151: 754-764.
3. Hunter DJ, Willett WC (1993) Diet, body size, and breast cancer [Review]. Epidemiol Rev 15: 110-132.
4. Feigelson HS, Henderson BE (1996) Estrogens and breast cancer: commentary. Carcinogenesis 17: 2279-2284.
5. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE (1990) Increased cell division as a cause of human cancer. Cancer Res 50: 7415-7421.
6. Yager JD, Liehr JG (1996) Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharacol Toxicol 36: 203-232.
7. Henderson BE, Feigelson HS (2000) Hormonal carcinogenesis. Carcinogenesis 21(3): 427-433.
8. Service RF (1998) New role for estrogen in cancer? Science 279: 1631-1633.
9. DeVita VT Jr, Hellman S, Rosenberg SA (1997) Cancer, Principles and Practice of Oncology. Philadelphia: J.P. Lippincott.
10. Weiss NS, Liff JM (1983) Accounting for the multicausal nature of disease in the design and analysis of epidemiologic studies. Am J Epidemiol 117: 14-18.
11. Potter JD, Cerhan JR, Sellers TA, et al. (1995) Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev 4: 319-326.
12. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG (2000) Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 151: 703-714.
13. Olsson H, Borg A, Ferno M, Ranstam J, Sigurdsson H (1991) HER-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones. J Natl Cancer Inst 83: 1483-1487.
14. Gammon MD, Hibshoosh H, Terry MB, et al. (1999) Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev 8: 413-419.
15. Huang W-Y, Newman B, Millikan RC, et al. (2000) Risk of breast cancer according to the status of HER-2/neu oncogene amplification. Cancer Epidemiol Biomarkers Prev 9: 65-71.
16. Vogelstein B, Kinzler KW (1993) The multistep nature of cancer. TIG 9: 138.
17. Lane D (1998) The promise of molecular oncology. Lancet 351 (Suppl 2): SI117-SI120.
18. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878.
19. Harris CC (1996) p53: at the crossroads of molecular carcinogenesis and molecular epidemiology. J Investig Dermatol Symp Proc 1: 115-118.
20. Olivier M, Hainaut P (2001) TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. Semin Cancer Biol 11: 353-360.
21. Yandell DW, Thor AD (1993) p53 analysis in diagnostic pathology. Biologic implications and possible clinical applications. Diagn Mol Pathol 2: 1-3.
22. Tsuda H, Hirohashi S (1994) Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. Int J Cancer 57: 498-503.
23. van der KK, Rookus MA, Peterse HL, van Leeuwen FE (1996) p53 protein overexpression in relation to risk factors for breast cancer. Am J Epidemiol 144: 924-933.
24. Gammon MD, Hibshoosh H, Terry MB, et al. (1999) Cigarette smoking and other risk factors in relation to p53 expression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev 8: 255-263.
25. Newman B, Moorman PG, Millikan R, et al. (1995) The Carolina breast cancer study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat 35: 51-60.
26. Aldrich TE, Vann D, Moorman PG, Newman B (1995) Rapid reporting of cancer incidence in a population-based study of breast cancer: one constructive use of a central cancer registry. Breast Cancer Res Treat 35: 61-64.
27. Weinberg CR, Sandler DP (1991) Randomized recruitment in case-control studies. Am J Epidemiol 134: 421-432.
28. Moorman PG, Newman B, Millikan R, Tse C-KJ, Sandler DP (1999) Participation rates in a case-control study: the impact of age, race and race of interviewer. Ann Epidemiol 9: 188-195.
29. Millikan R, Pittman G, Newman B, et al. (1998) Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7: 371-378.
30. Furberg H, Newman B, Moorman P, Millikan R (1999) Lactation and breast cancer risk. Int J Epidemiol 28: 396-402.
31. Moorman PG, Millikan RC, Newman B (2001) Oral contraceptives and breast cancer among African-American women and white women. J Natl Med Assoc 93: 329-334.
32. Dressler LG, Geradts J, Burroughs M, Cowan D, Millikan RC, Newman B (1999) Policy guidelines for the utilization of formalin-fixed, paraffin-embedded tissue sections: the UNC SPORE experience. University of North Carolina Specialized Program of Research Excellence. Breast Cancer Res Treat 58: 31-39.
33. Sas Institute Inc. (1988) SAS/STAT User's Guide, Release 6.03 Edition. Cary, NC: SAS Institute Inc.
34. Yarbro JW, Page DL, Fielding LP, Partridge EE, Murphy GP (1999) American Joint Committee on Cancer prognostic factors consensus conference. Cancer 86: 2436-2446.
35. Begg CB, Zhang ZF (1994) Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomarkers Prev 3: 173-175.
36. Furberg H, Millikan RC, Geradts J, et al. (2002) Environmental exposures in relation to breast cancer characterized by p53 expression. Cancer Epidemiol Biomarkers Prev 11: 829-835.
37. De Benedetti VM, Welsh JA, Yu MC, Bennett WP (1996) p53 mutations in hepatocellular carcinoma related to oral contraceptive use. Carcinogenesis 17: 145-149.
38. Armes JE, Trute L, White D, et al. (1999) Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 59: 2011-2017.
39. Crook T, Crossland S, Crompton MR, Osin P, Gusterson BA (1997) p53 mutations in BRCA1-associated familial breast cancer. Lancet 350: 638-639.
40. Glebov OK, McKenzie KE, White CA, Sukumar S (1994) Frequent p53 gene mutations and novel alleles in familial breast cancer. Cancer Res 54: 3703-3709.
41. Shields PG, Harris CC (1991) Molecular epidemiology and the genetics of environmental cancer. JAMA 266: 681-687.
42. Chappuis PO, Kapusta L, Begin LR, et al. (2000) Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol 18: 4045-4052.
43. Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD (2001) TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 61: 4092-4097.
44. Abbott DW, Thompson ME, Robinson-Benion C, Tomlinson G, Jensen RA, Holt JT (1999) BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem 274: 18808-18812.
45. Vahakangas KH, Samet JM, Metcalf RA, et al. (1992) Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 339: 576-580.
46. Elledge RM, Allred DC (1998) Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 52: 79-98.